For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| General and administrative expenses | 578,698 | 5,328,284 | 904,346 | 1,049,903 |
| Research and development expenses | 524,781 | 496,543 | 412,639 | 496,197 |
| Total operating costs | 1,103,479 | 5,824,827 | 1,316,985 | 1,546,100 |
| Interest income | 44,909 | 51,820* | 15,697 | - |
| Other expense | - | -24,251* | 12,441 | - |
| Loss from equity method investment | -91,582 | -234,565* | 176,056 | - |
| Total other income (expense), net | -46,673 | -158,494 | - | -107 |
| Interest income | - | - | - | 8,495 |
| Other income, expense, net | - | - | 179,312 | - |
| Net loss | -1,150,152 | -5,983,321 | -1,137,673 | -1,537,712 |
| Deemed dividend | - | 0 | 21,556,821 | - |
| Net gain attributable to common stockholders | - | -5,983,321 | -22,694,494 | - |
| Basic EPS | -0.03 | -0.143 | -1.18 | -0.09 |
| Diluted EPS | -0.03 | -0.338* | -1.18 | -0.09 |
| Basic Average Shares | 41,941,370 | 41,870,778 | 19,274,947 | 16,986,488 |
| Diluted Average Shares | - | - | 19,274,947 | 16,986,488 |
MIRA PHARMACEUTICALS, INC. (MIRA)
MIRA PHARMACEUTICALS, INC. (MIRA)